Navigation Links
Scientists discover new genetic immune disorder in children
Date:6/4/2009

Your immune system plays an important function in your healthit protects you against viruses, bacteria, and other toxins that can cause disease. In autoinflammatory diseases, however, the immune system goes awry, causing unprovoked and dangerous inflammation. Now, researchers from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health, and other institutions have discovered a new autoinflammatory syndrome, a rare genetic condition that affects children around the time of birth. The findings appear in the current issue of the New England Journal of Medicine.

The scientists have termed the new autoinflammatory syndrome DIRA (deficiency of the interleukin-1 receptor antagonist). Children with the disorder display a constellation of serious and potentially fatal symptoms that include swelling of bone tissue; bone pain and deformity; inflammation of the periosteum (a layer of connective tissue around bone); and a rash that can span from small individual pustules to extensive pustulosis that covers most of the patient's body. Most of the children begin to have symptoms from birth to 2 weeks of age.

"The beauty of this discovery is that the symptoms of this devastating disease can now be treated," said NIAMS director and immunodermatologist, Stephen I. Katz, M.D., Ph.D. "The abnormal inflammatory pathways seen in this disease may also help us understand other common diseases that share clinical features, such as psoriasis, as well as other autoinflammatory disorders."

"We knew when we saw these children that we were dealing with a previously unrecognized autoinflammatory syndrome. The clinical characteristics were distinct from other diseases we had seen before," said NIAMS researcher and lead author Raphaela Goldbach-Mansky, M.D., M.H.S. When her colleague, Dr. Ivona Aksentijevich, tested the first patient for genetic abnormalities, their suspicions were confirmed, and ultimately abnormalities were found in a number of other cases.

All the children had inherited mutations in IL1RN, a gene that encodes a protein known as interleukin-1 receptor antagonist (IL-1Ra). IL-1Ra binds to the same cell receptors as the inflammatory protein interleukin-1, and acts as a brake on this inflammatory protein. Without IL-1Ra, the children's bodies cannot control systemic inflammation that can be caused by interleukin-1.

The scientists identified nine patients from six families with DIRA in the Canadian province of Newfoundland, the Netherlands, Lebanon, and Puerto Rico. Those who were alive at the time of diagnosissix in allwere treated with anakinra, a drug that is normally used for rheumatoid arthritis and is a synthetic form of human IL-1Ra. Although the patients were resistant to other medications such as steroids, most responded successfully and immediately to anakinra. "Our first patient had been unresponsive to several treatments, and his health care team had almost given up. But with anakinra, he was out of the hospital in 10 days and his symptoms resolved," Dr. Goldbach-Mansky said.

Although the mutation that causes DIRA is rare, as many as 2.5 percent of the population of northwest Puerto Rico are carriers. Since DIRA is recessively inherited, these data suggest that it may be present in about 1 in 6,300 births in this population. Because the mutation was found in three independent Dutch families, newborn screening for DIRA in this population, as well as that of northwest Puerto Rico, may be warranted, Dr. Goldbach-Mansky said.

"The DIRA discovery can be attributed to an innovative and collaborative effort between clinicians and laboratory researchers at NIAMS and an international team of dedicated investigators," said NIAMS Clinical Director and coauthor Daniel L. Kastner, M.D., Ph.D. "Moreover, the unveiling of this novel autoinflammatory syndrome provides us with a tool to further dissect the role of interleukin-1 in human biology and disease."


'/>"/>

Contact: Trish Reynolds
reynoldsp2@mail.nih.gov
301-496-8190
NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases
Source:Eurekalert

Related biology news :

1. UK scientists working to help cut ID theft
2. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
3. Comet probes reveal evidence of origin of life, scientists claim
4. Scientists link fragile X tremor/ataxia syndrome to binding protein in RNA
5. Male elephants get photo IDs from scientists
6. Scientists retrace evolution with first atomic structure of an ancient protein
7. Muscle mass: Scientists identify novel mode of transcriptional regulation during myogenesis
8. Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs
9. Clemson scientists shed light on molecules in living cells
10. Scientists tackle mystery mountain illness
11. T. rex quicker than Becks, say scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, ... Simple," and 23andMe , the leading personal genetics ... choices.  Zipongo can now provide customers with personalized nutrition ... goals and biometrics, but also genetic markers impacting how ... Zipongo,s personalized food decision support platform uses biometrics ...
(Date:3/7/2017)...   HireVue , the leading provider of video ... best talent, faster, today announced the additions of ... Diana Kucer as Chief Marketing Officer (CMO). ... poised to drive continued growth in the company,s new ... record bookings in 2017. "Companies worldwide turn ...
(Date:3/2/2017)... -- Summary This report provides all the information ... and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , March 23, 2017  Northwest Biotherapeutics ... DCVax® personalized immune therapies for solid tumor cancers, ... $7.5 million financing it announced last Friday, March ... to several institutional investors securities totaling 28,843,692 shares, ... share, and 10,000,000 shares of Class C Warrants ...
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... today announced the hire of Dr. Sigmund “Sig” Floyd as Vice President ? ... partnerships and joint development activities. , “Dr. Floyd’s career has spanned 30 years ...
(Date:3/22/2017)... 2017 Good Start Genetics, a leading family ... 130 million covered lives mark through its most recent ... Texas . With newly signed contracts nationally and ... strong payor acceptance based on the quality of its ... counseling, its industry-leading customer care and support and its ...
Breaking Biology Technology: